A clinical plan for MDMA (Ecstasy) in the treatment of posttraumatic stress disorder (PTSD): partnering with the FDA.

Abstract

The FDA and the Spanish Ministry of Health have concluded that the risk/benefit ratio is favorable under certain circumstances for clinical studies investigating MDMA-assisted psychotherapy. Both agencies have approved pilot studies in chronic posttraumatic stress disorder (PTSD) patients who have failed to obtain relief from at least one course of conventional treatment. These studies, the only ones in the world into the therapeutic use of MDMA, are being funded by a nonprofit research and educational organization, the Multidisciplinary Association for Psychedelic Studies (MAPS, www.maps.org). A rationale is offered explaining why MAPS chose to focus its limited resources on MDMA, and also on PTSD patients. A Clinical Plan is elaborated for the conduct of the "adequate and well-controlled" trials necessary to evaluate the safety and efficacy of MDMA-assisted psychotherapy for PTSD, with the studies estimated to cost about 5 million dollars and to take about five years. The Clinical Plan has been developed, in part, through analysis of the studies conducted by Pfizer in its successful effort to have Zoloft approved by the FDA for use with PTSD patients, and through review of transcripts of the FDA's Psychopharmacologic Drugs Advisory Committee meeting that recommended approval of Zoloft for PTSD.

• Authors: Rick Doblin
• Journal: Journal of psychoactive drugs (J Psychoactive Drugs) 2002 Apr-Jun Vol. 34 Issue 2 Pg. 185-94 ISSN: 0279-1072 [Print] United States
• PMID: 12691208 (Publication Type: Journal Article, Review)

Chemical References

• N-Methyl-3,4-methylenedioxyamphetamine

Topics

• Animals
• Clinical Trials as Topic (methods)
• Epilepsy, Post-Traumatic (drug therapy, psychology)
• Humans
• N-Methyl-3,4-methylenedioxyamphetamine (therapeutic use)
• United States
• United States Food and Drug Administration (legislation & jurisprudence)